Format

Send to:

Choose Destination
See comment in PubMed Commons below
Eur J Immunol. 2013 Mar;43(3):576-9. doi: 10.1002/eji.201243275. Epub 2013 Feb 4.

Adaptive resistance: a tumor strategy to evade immune attack.

Author information

  • 1Department of Immunobiology and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT 06519, USA.

Abstract

A dilemma in cancer immunology is that, although patients often develop active antitumor immune responses, the tumor still outgrows. It has become clear that under the pressure of the host's immune system, cancer cells have adapted elaborate tactics to reduce their immunogenicity (also known as immunoselection) and/or to actively suppress immune cells and promote immune tolerance (also known as immunosubversion). In this issue of the European Journal of Immunology, Dolen and Esendagli [Eur. J. Immunol. 2013. 43: 747-757] show that acute myeloid leukemia (AML) cells develop an adaptive immune phenotype switching mechanism: In response to attack by activated T cells, the leukemia cells quickly downregulate the T-cell costimulatory ligand B7-H2 and reciprocally upregulate the coinhibitory ligands B7-H1 and B7-DC in order to shut down T-cell activation via the PD-1 pathway. These novel findings and their relevance for cancer immunotherapy, especially potential applications in PD-1 check-point blockade therapy are discussed in this Commentary.

© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

PMID:
23381914
[PubMed - indexed for MEDLINE]
PMCID:
PMC4135307
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk